摘要
胃癌是常见的癌症相关死亡原因。早期胃癌的长期总生存率已有显著提高,但是进展期胃癌的预后仍然很差。胃癌TNM分期是主要的预后指标,但是对于具有相同TNM分期且接受相同治疗的患者,其预后仍有不同。因此,需要新的可与TNM分期相结合的分子预后标记物用以指导临床诊断和治疗。本文将对胃癌分子预后标记物的研究进展及其临床意义进行综述。
Gastric carcinoma is the common cause of cancer-related death. Though long-term overall survival （OS） rate of early gastric carcinoma has been significantly improved, the prognosis of advanced gastric carcinoma still remains poor. TNM stage is the main prognostic factor of gastric carcinoma. But gastric carcinoma patients with the same TNM stage, receiving the same treatments, have different clinical outcomes. Therefore, new prognostic biomarkers in conjunction with the TNM-staging information are required. In this paper, we will review the research on advance of gastric carcinoma molecular prognostic biomarkers and their clinical application.
出处
《临床肿瘤学杂志》
CAS
2012年第6期568-572,共5页
Chinese Clinical Oncology
关键词
胃癌
分子标记物
预后
Gastric carcinoma
Molecular biomarker
Prognosis
